Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 22 Dec 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Jun 2017.